

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Results from the Phase III IMpassion130 trial _____ a significant improvement in progression-free survival with the addition of atezolizumab to *nab* paclitaxel as first-line treatment for metastatic TNBC.
a. Demonstrated
b. Did not demonstrate
- In a follow-up analysis of the APT trial evaluating adjuvant paclitaxel/trastuzumab for HER2-positive, node-negative BC, the 7-year disease-free survival rate was approximately _____.
a. 3%
b. 50%
c. 93%
- Updated results from the TEXT and SOFT trials included a statistically significant improvement in freedom from distant recurrence among premenopausal women with ER-positive, HER2-negative BC who received adjuvant exemestane and ovarian function suppression compared to tamoxifen alone.
a. True
b. False
- Which of the following categories reflects the mechanism of action of alpelisib (BYL719)?
a. Antibody-drug conjugate
b. Anti-PD-1/PD-L1 antibody
c. CDK4/6 inhibitor
d. PI3 kinase inhibitor
e. Tyrosine kinase inhibitor
- In the Phase III TAILORx study evaluating adjuvant therapy for patients with hormone receptor-positive, HER2-negative, node-negative BC and an intermediate RS of 11 to 25, adjuvant endocrine therapy alone was _____ to chemoendocrine therapy in terms of invasive disease-free survival in the overall patient population.
a. Inferior
b. Noninferior
- Which of the following CDK4/6 inhibitors appears to penetrate the CNS more effectively than do the others?
a. Abemaciclib
b. Palbociclib
c. Ribociclib
d. None of the above (all appear to penetrate the CNS equally)
- Exploratory analyses of the TAILORx trial results suggest a potential benefit with chemotherapy for _____ patients with an intermediate-range RS, particularly those with a score between 16 and 25.
a. Premenopausal
b. Postmenopausal
c. Neither a nor b
- The Phase III RxPONDER study randomly assigns patients with ER-positive, HER2-negative, node-negative BC and a RS of 25 or higher to adjuvant endocrine therapy with or without chemotherapy.
a. True
b. False
- Which of the following categories reflects the mechanism of action of tucatinib?
a. Anti-PD-1/PD-L1 antibody
b. CDK4/6 inhibitor
c. Tyrosine kinase inhibitor
- In the Phase III PALOMA-3 study, the addition of palbociclib to fulvestrant resulted in a statistically significant improvement in overall survival for patients with HR-positive, HER2-negative advanced BC who were sensitive to previous endocrine therapy.
a. True
b. False